Xenon Pharmaceuticals nets $24.3mm in FOPO

15:40 EDT 22 Sep 2016 | Elsevier Business Intelligence

Nasdaq-traded Canadian biotech Xenon Pharmaceuticals Inc. (drug discovery for rare diseases) netted $24.3mm through the public sale of 3.45mm shares (including the overallotment) at $7.50. Selling shareholders also sold 1.15mm shares. The company will use proceeds to fund further development of Phase II XEN801, an SCD1 inhibitor for acne; preclinical development of its Nav1.6 sodium channel inhibitor in childhood epilepsy disorders (for which an IND is expected in mid-2017); as well as continued research activities for its Extreme Genetics platform (for rare human disease target validation) and ion channel drug discovery programs.

Original Article: Xenon Pharmaceuticals nets $24.3mm in FOPO


More From BioPortfolio on "Xenon Pharmaceuticals nets $24.3mm in FOPO"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...